Equities Analysts Offer Predictions for EW Q2 Earnings

Edwards Lifesciences Co. (NYSE:EW - Free Report) - Investment analysts at Zacks Research lifted their Q2 2025 earnings per share estimates for Edwards Lifesciences in a research report issued on Wednesday, December 11th. Zacks Research analyst R. Department now expects that the medical research company will post earnings per share of $0.62 for the quarter, up from their prior estimate of $0.61. The consensus estimate for Edwards Lifesciences' current full-year earnings is $2.56 per share. Zacks Research also issued estimates for Edwards Lifesciences' FY2025 earnings at $2.43 EPS and Q1 2026 earnings at $0.67 EPS.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its quarterly earnings results on Thursday, October 24th. The medical research company reported $0.67 EPS for the quarter, meeting analysts' consensus estimates of $0.67. The company had revenue of $1.35 billion for the quarter, compared to analyst estimates of $1.57 billion. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. The company's quarterly revenue was up 8.9% compared to the same quarter last year. During the same period last year, the company earned $0.59 earnings per share.

A number of other research analysts have also issued reports on the company. Truist Financial reaffirmed a "hold" rating and set a $78.00 target price (up from $70.00) on shares of Edwards Lifesciences in a report on Thursday, December 5th. Bank of America raised Edwards Lifesciences from a "neutral" rating to a "buy" rating and lifted their target price for the stock from $82.00 to $90.00 in a report on Monday. Royal Bank of Canada lifted their target price on Edwards Lifesciences from $80.00 to $85.00 and gave the stock an "outperform" rating in a report on Thursday, December 5th. Evercore ISI lowered their target price on Edwards Lifesciences from $76.00 to $70.00 and set an "in-line" rating on the stock in a report on Tuesday, October 1st. Finally, JPMorgan Chase & Co. lifted their target price on Edwards Lifesciences from $72.00 to $78.00 and gave the stock a "neutral" rating in a report on Friday, October 25th. Sixteen analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus target price of $79.40.

Edwards Lifesciences Stock Performance

Shares of EW traded up $0.59 during trading hours on Monday, reaching $73.91. 5,992,934 shares of the company's stock traded hands, compared to its average volume of 4,648,238. The firm has a market capitalization of $43.59 billion, a price-to-earnings ratio of 10.67, a P/E/G ratio of 3.63 and a beta of 1.12. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. Edwards Lifesciences has a twelve month low of $58.93 and a twelve month high of $96.12. The business's fifty day simple moving average is $69.42 and its two-hundred day simple moving average is $73.90.

Insider Activity

In related news, VP Donald E. Bobo, Jr. sold 5,000 shares of the business's stock in a transaction that occurred on Tuesday, October 15th. The stock was sold at an average price of $69.51, for a total value of $347,550.00. Following the completion of the sale, the vice president now directly owns 46,936 shares in the company, valued at approximately $3,262,521.36. The trade was a 9.63 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, VP Daniel J. Lippis sold 2,500 shares of Edwards Lifesciences stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of $74.08, for a total value of $185,200.00. Following the completion of the transaction, the vice president now directly owns 23,189 shares in the company, valued at approximately $1,717,841.12. This represents a 9.73 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 37,500 shares of company stock worth $2,508,350 in the last three months. 1.29% of the stock is owned by insiders.

Institutional Trading of Edwards Lifesciences

A number of institutional investors and hedge funds have recently modified their holdings of EW. FSA Wealth Management LLC bought a new stake in shares of Edwards Lifesciences during the third quarter valued at approximately $30,000. Prospera Private Wealth LLC bought a new stake in shares of Edwards Lifesciences during the third quarter valued at approximately $32,000. Avior Wealth Management LLC boosted its stake in Edwards Lifesciences by 138.7% in the 3rd quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company's stock valued at $35,000 after buying an additional 308 shares in the last quarter. Peoples Bank KS acquired a new stake in Edwards Lifesciences in the 3rd quarter valued at $40,000. Finally, JFS Wealth Advisors LLC boosted its stake in Edwards Lifesciences by 31.1% in the 3rd quarter. JFS Wealth Advisors LLC now owns 700 shares of the medical research company's stock valued at $46,000 after buying an additional 166 shares in the last quarter. 79.46% of the stock is currently owned by institutional investors.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.